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Abstract
Background: Acute severe childhood asthma is an infrequent, but potentially life-threatening emergency
condition. There is a wide range of different approaches to this condition, with very little supporting evidence,
leading to significant variation in practice. To improve knowledge in this area, there must first be consensus on
how to conduct clinical trials, so that valid comparisons can be made between future studies. We have formed an
international working group comprising paediatricians and emergency physicians from North America, Europe, Asia,
the Middle East, Africa, South America, Central America, Australasia and the United Kingdom.
Methods/design: A 5-stage approach will be used: (1) a comprehensive list of outcomes relevant to stakeholders
will be compiled through systematic reviews and qualitative interviews with patients, families, and clinicians; (2)
Delphi methodology will be applied to reduce the comprehensive list to a core outcome set; (3) we will review
current clinical practice guidelines, existing clinical trials, and literature on bedside assessment of asthma severity.
We will then identify practice differences in tne clinical assessment of asthma severity, and determine whether
further prospective work is needed to achieve agreement on inclusion criteria for clinical trials in acute paediatric
asthma in the emergency department (ED) setting; (4) a retrospective chart review in Australia and New Zealand
will identify the incidence of serious clinical complications such as intubation, ICU admission, and death in children
hospitalized with acute severe asthma. Understanding the incidence of such outcomes will allow us to understand
how common (and therefore how feasible) particular outcomes are in asthma in the ED setting; and finally (5) a
meeting of the Pediatric Emergency Research Networks (PERN) asthma working group will be held, with invitation
of other clinicians interested in acute asthma research, and patients/families. The group will be asked to achieve
consensus on a core set of outcomes and to make recommendations for the conduct of clinical trials in acute
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severe asthma. If this is not possible, the group will agree on a series of prioritized steps to achieve this aim.
Discussion: The development of an international consensus on core outcomes is an important first step towards
the development of consensus guidelines and standardised protocols for randomized controlled trials (RCTs) in this
population. This will enable us to better interpret and compare future studies, reduce risks of study heterogeneity
and outcome reporting bias, and improve the evidence base for the management of this important condition.
Background
Asthma is a frequent reason for a child to attend the
emergency department (ED) [1, 2], and one of the most
common reasons for paediatric hospitalization after an
ED visit [3]. In the USA, the rate of paediatric ED visits
for asthma increased by 13.3% between 2001 and 2010
[4], whilst in the UK it is estimated that a child is admit-
ted to hospital every 20 min due to an asthma attack [5].
Most children with asthma have mild or moderate exac-
erbations, and respond to first-line treatment with inhaled
bronchodilator therapy and systemic steroids [6–9]. How-
ever, a proportion of children with severe asthma require
more intensive therapies including intravenous (IV) medi-
cations, endotracheal intubation and/or admission to in-
tensive care [9–11]. Management of acute severe asthma
is complicated by a number of problems, including a large
number of treatment options and wide variation in self-
reported and actual practice [12].
Treatment options for acute severe paediatric asthma
Medications used for acute severe paediatric asthma
include IV bronchodilators (such as salbutamol/albu-
terol [13], terbutaline [14], magnesium [15], or ami-
nophylline [16]), nebulized magnesium [17], inhaled
heliox [18], and IV ketamine [19]. Respiratory support
with non-invasive and/or invasive ventilation may also
be used if there is a poor response to intensive medical
treatment [20].
A Cochrane review of the addition of IV beta2-agonists
to inhaled beta2-agonists concluded that until further
high-quality, adequately powered trials are conducted, “it
is not possible to form a robust evaluation of the addition
of IV beta2-agonists in … severe acute asthma” [13].
Intravenous magnesium sulphate (MgSO4) appears to
be safe and beneficial in severe asthma in adults [21].
Data on the use of MgSO4 in children are not as robust,
but appear promising [15]. Inhaled MgSO4 is also used
in acute severe asthma [22], although recent research
has not confirmed a clinical benefit, rather that “no
harm is done” and that it “may be helpful” in some
patients [17].
When added to inhaled bronchodilators and systemic
corticosteroids, IV aminophylline may lead to an earlier
improvement in lung function, but may be associated
with a significant increase in the rate of vomiting [23].
There is insufficient evidence for any effect of aminoph-
ylline infusion on other useful clinical outcomes such as
reducing the intubation rate, frequency of intensive care
admission, or hospital length of stay [24, 25]. Cochrane
reviews of heliox [18] and ketamine [26] as therapies for
severe asthma have not demonstrated any consistent
benefit.
Variation in practice
Given the lack of useful comparative studies, variation in
the management of acute severe asthma in children is
considerable. A recent survey in the UK and Ireland
found that over half of front-line emergency and general
paediatricians preferred salbutamol as first-line IV treat-
ment, whilst 28% preferred MgSO4, and 15% preferred
aminophylline [12]. An earlier survey of paediatric emer-
gency physicians in Australia and New Zealand found
that aminophylline was used by 45%, IV MgSO4 by 55%,
and IV salbutamol by 87% of respondents [27]. Whilst
magnesium and salbutamol are listed as second-line and
third-line bronchodilators for management of acute
severe paediatric asthma in all Australian guidelines
[28], only some guidelines include aminophylline [29]. A
recent prospective study in 24 EDs in the UK and
Ireland found wide variation in the use of IV broncho-
dilator treatment for acute paediatric asthma ranging
from 0% to 19.4% [11].
The United States National Heart, Lung and Blood
Institute (NHLBI) Expert Panel Report guidelines sug-
gest IV MgSO4 or inhaled heliox for impending respira-
tory failure or persistently severe asthma. The guidelines
state there are insufficient data to make recommenda-
tions on intravenous beta2-agonists and IV leukotriene
receptor antagonists, and specifically recommend against
aminophylline [30].
British guidelines recommend considering IV MgS04,
IV aminophylline, or IV salbutamol for a child with
severe or life-threatening asthma unresponsive to first-
line treatment, with a preference for use of MgS04 as the
first option [31].
The Global Initiative for Asthma (GINA) guidelines
for acute severe asthma recommend against IV ami-
nophylline. The guidelines suggest that IV MgSO4 can
be considered for acute severe asthma, and that IV
terbutaline may be given to a severely ill child where
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inhaled therapy is not possible, although there is “no
evidence to support the routine use of IV beta2-ago-
nists in patients with severe asthma exacerbations”
[32]. Thus, there is considerable geographic variation
in clinician preference, guidelines, and actual use of
IV agents for acute severe paediatric asthma, reflect-
ing the overall paucity of high-quality evidence to in-
form clinicians [16].
Consistent outcome measures are lacking
Previous reviews of acute asthma have not been success-
ful in making meaningful comparisons between treat-
ments, due to the varying outcome measures used in
many trials [23, 25]. Inconsistent selection, measure-
ment, and reporting of outcomes has been noted both in
selecting domains and measurement instruments. These
issues could be addressed with the development and ap-
plication of agreed standardized sets of outcomes, i.e.
“core outcome sets”, that are important to relevant
stakeholders [33]. These could include subjective mea-
sures relevant to patients, economic outcomes, and
physiologic outcomes (such as asthma severity scores)
[22]. Review authors have suggested the need to focus
on clinically important outcomes such as frequency of
admission to hospital and the intensive care unit (ICU),
length of hospital stay, and relapse rates [13].
Acute asthma has been highlighted as a research prior-
ity by multiple paediatric emergency medicine research
networks [34–36]. However, meaningful progress is un-
likely until there is consensus on a set of core outcome
measures that are relevant to clinicians, patients,
families, and healthcare funders.
Context – Pediatric Emergency Research Networks (PERN)
Over the last 10 years, there has been significant world-
wide collaboration between major Pediatric Emergency
Research Networks. The Pediatric Emergency Research
Networks (PERN) collaboration involves research orga-
nisations from USA, Canada, Europe, Spain, the UK and
Ireland, Australia and New Zealand, and South and Cen-
tral America, as well as contributions from additional
countries outside a formal research network [37]. The
collaboration has enabled a number of successful inter-
national multicentre projects to be completed [38–43].
Aims and objectives
Aims
The PERN asthma working group was formed in 2017,
with the aims of developing consensus evidence-based
acute asthma outcome measures (with the input of pa-
tients, families, and clinicians), and international consen-
sus guidelines for the conduct and reporting of clinical
trials of therapies for acute asthma exacerbations in chil-
dren attending emergency departments. We aim for our
core outcome set to be applicable to children with severe
acute asthma receiving any therapeutic intervention, in-
cluding inhaled therapies, parenteral treatment, or oxy-
gen/ventilatory therapy. Currently, the working group
comprises emergency physicians and paediatricians from
seventeen countries. This paper describes the proposed
methodology for our work (current as of July 2019),
which has been registered with the Core Outcome Mea-
sures in Effectiveness Trials (COMET) initiative [44].
Methods/design
Overview
Core outcome set development will follow recent guid-
ance from the COMET initiative [45]. A five-stage
approach will be used (Fig. 1). A comprehensive list of
outcomes relevant to stakeholders will be compiled
through a systematic review of outcomes reported in
existing trials, supplemented by qualitative interview
studies with patients, families, and clinicians. Second,
the comprehensive list will be reduced to a core out-
come set using Delphi methodology involving patients,
families, and clinicians.
Third, to inform consensus discussions on inclusion
criteria and outcome selection for future RCTs in acute
severe paediatric asthma in the ED setting, we will re-
view current clinical practice guidelines, existing clinical
trials, and literature on bedside asthma severity scores.
We will then identify practice differences in bedside
assessment of asthma severity, and determine whether
further prospective work is needed.
Fourth, a retrospective chart review in Australia and
New Zealand will enable us to identify the incidence of
serious clinical complications such as intubation, ICU
admission, and death in children hospitalized with acute
severe asthma. Understanding the incidence of such
outcomes will allow us to understand how common
(and therefore how feasible) particular outcomes are in
asthma in the ED setting.
Finally, a meeting of the PERN asthma working group
will be held, with invitation of other clinicians interested
in acute asthma research, and patients/families. Results
of the initial steps outlined above will be presented, and
the group will be asked to achieve consensus on a core
set of outcomes and to make recommendations for the
conduct of clinical trials on acute severe asthma. If this
is not possible, the group will agree on a series of priori-
tized steps to achieve this aim.
Project 1: developing a comprehensive list of outcome
measures
In order to develop a comprehensive list of outcome
measures, we have performed a systematic review of out-
comes reported in existing trials, which will be comple-
mented by an overview of Cochrane Reviews, and
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qualitative interview studies with patients, families, and
clinicians.
Systematic review
We have recently conducted a systematic review of pri-
mary and secondary outcomes used in trials of IV bron-
chodilators in children with acute severe asthma. We
searched MEDLINE, EMBASE, Cochrane CENTRAL,
and the World Health Organization International Clin-
ical Trials Registry Platform for randomized trials in
children (younger than 18 years) with acute severe
asthma, comparing IV bronchodilator therapy to another
treatment.
Data extraction included authors, year of publication,
geographic location, number of patients, primary, second-
ary, and other outcomes used, and study interventions in-
cluding dosing and timing of medication administered. The
systematic review was prospectively registered in the PROS-
PERO database (CRD42017055331), and has recently been
published [46]. We identified 35 published papers and four
registered study protocols. We identified 56 primary out-
comes, the most common being a clinical asthma score
(23/56; 41%). Other primary outcomes identified included
bedside tests of respiratory function (11/56; 20%) and mea-
sures of length of stay (9/56; 16%). There were a total of 60
different secondary outcomes; the most common were
various measures of length of stay (24/60; 40%) and adverse
events (11/60; 18%) [46].
Overview of Cochrane Reviews
Members of the PERN asthma working group are also
undertaking an overview of Cochrane Reviews to
summarize Cochrane Reviews on the efficacy and safety
of interventions for escalation of therapy for acute exac-
erbations of asthma in children. The protocol for this
overview has been published [47]. Additional objectives
of the overview are to (1) identify gaps in the current
evidence base that will inform recommendations for fu-
ture research and subsequent Cochrane Reviews; and (2)
to categorize information on reported outcome mea-
sures used in trials of escalation of treatment for acute
exacerbations of asthma in children.
Qualitative interview studies: patients/families and
clinicians
This part of the project aims to assess the perspectives
of patients, families, and clinicians regarding their ex-
perience of acute severe paediatric asthma. Qualitative
methods are recommended to identify outcomes import-
ant to stakeholders, help understand why these out-
comes are important, and identify appropriate language
to use when presenting these outcomes in later surveys
Fig. 1 Overview of methodology to develop core outcome set in acute severe paediatric asthma
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[48]. These perspectives will be combined with a similar
study of clinicians, and the results of the systematic re-
view to develop a comprehensive list of outcome mea-
sures. This list will directly inform the development of a
planned Delphi survey (see below).
To ensure global representation and maximum diver-
sity, we aim to analyse the perspectives from a number
of patient and clinician groups from multiple hospitals
in a variety of settings around the world. Patients and
families will be purposively sample d[45], with selection
of children with recent experience of acute severe
asthma exacerbations requiring attendance in an emer-
gency department and admission to hospital, managed
in a variety of hospitals in a variety of healthcare sys-
tems. We aim to include clinician groups from multiple
EDs, paediatric wards, and ICUs. Initially, we will select
clinicians from the already established asthma working
group, and then - if further participants are required -
expand to include intensive care physicians and hospital-
ists/paediatricians.
The specific objectives of the patient/family interviews
are to (1) determine which aspects of clinical care and
which outcomes are most important to patients and
families in this setting; (2) determine the underlying rea-
sons why these outcomes are important; and (3) identify
possible participants for a patient steering group and
participation in a consensus meeting. For the clinician
interviews, our first two objectives are the same as for
the patient/family interviews, whilst a third objective is
to determine how clinicians define acute severe exacer-
bation of asthma.
Ethics approval for the interview studies has been ob-
tained in Australia; additional local ethics approval will
be sought where relevant. An overview of the methods
of the interview studies for clinicians and patients/fam-
ilies is presented in Table 1.
Invitations to participate will be distributed via email
through the partner networks that contribute to PERN,
and to clinicians associated with the PERN asthma
working group. Copies of the interview schedules are
available as Additional files 1 and 2.
To provide a clinical context to each patient interview,
there will be focused review of the relevant medical re-
cords for included patients. We will extract details of the
patient’s age, gender, previous asthma history, and treat-
ment administered during the index hospitalisation.
Data analysis
Any identifying data will be removed from the interview
transcript prior to analysis. Patient family interviews
conducted in a language other than English will be
translated into English for the purpose of analysis. The
translation will be checked by the original interviewer.
Thematic analysis will be performed independently by
the principal investigator for each study (SC for the pa-
tient/family interview study and CG for the clinician
interview study) and one other investigator, based upon
the taxonomy developed for outcomes in medical re-
search, comprising mortality/survival, physiological/clin-
ical, life impact, resource use, and adverse events/effects
[49]. Additional taxonomy based on the Theoretical Do-
mains Framework (TDF) [50] will be used for the clin-
ician interviews. The themes and coding will then be
reviewed and cross-checked by the original interviewer.
N-vivo qualitative analytic software (QSR International,
Melbourne, Australia) will be used for analysis.
Sample size
Due to the qualitative nature of the studies, we have not
pre-determined a sample size. Table 1 provides details
on how thematic saturation will be determined for each
study. We are aiming to obtain representative views
from diverse populations around the world, so anticipate
the involvement of at least ten hospitals for each study.
Data management and storage
De-identified transcripts will be collected and stored in a
password-protected file at Monash Health, Melbourne,
Australia (patient interview study) and at Women and
Children’s Hospital, Adelaide (clinician interview study).
As per the National Health & Medical Research Council,
we will keep original data for at least 7 years.
Ethical aspects
The patient interview study has been approved by the
Monash Health Human Research Ethics Committee
(RES-18-0000-530A), whilst the clinician interview study
has been approved by the Women’s and Children’s
Health Network Human Research Ethics Committee
(HREC/18/WCHN/120). Site-specific approval will be
obtained at each site prior to commencement of local
data collection.
Project 2: prioritising outcome measures: Delphi process
With information from systematic reviews and qualita-
tive interviews, we will develop a comprehensive list of
outcome measures. We will then conduct a prioritization
exercise using modified Delphi methodology.
We intend to have two independent panels for the
Delphi study: a patient/family panel and a clinician/re-
searcher panel. Those participating in the qualitative re-
search projects will be invited to participate in the
Delphi study. Similar patient/family participants will be
recruited from hospitals involved in the PERN member
networks, and third-party asthma organisations, such as
the National Asthma Council Australia, Asthma UK,
Asthma and Allergy Foundation of America, and
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Asthma Canada. Additional clinician/researcher partici-
pants will be recruited through the PERN member net-
works and circulation of an invitation email by members
of the PERN asthma working group to their local and
national paediatric and/or emergency medicine orga-
nisations. Social media will also be used to recruit
participants.
Due to the importance of minimising attrition during
the Delphi process [45], the requirement for participants
to complete all rounds will be emphasized during re-
cruitment, and reinforced during the informed consent
process and ongoing communications (for example,
using email reminders) once the study has commenced.
The list of outcomes will be presented in plain, non-
technical language. We intend to use an online survey
platform such as Delphi Manager (http://cometinitiative.
org/DelphiManager/) to conduct the study, and plan to
create and circulate simultaneous surveys in English,
Spanish, and potentially other languages to allow partici-
pation of patients, families, and clinicians based in the
various countries contributing to the project. Reminders
will be sent to non-responders at weekly intervals for 2
weeks for each round of the Delphi study. All questions
and free-text responses will be professionally translated.
Prior to commencement, we will seek approval from
relevant human research ethics committees.
Delphi round 1
In the first round, participants will be registered on line,
and provide basic demographic information. Clinicians/
Table 1 Methodology for qualitative interview studies
Patient/family interview study Clinician interview study
Hospital selection • Ability to conduct the patient interviews
• Overall diversity (geographic, health system, and socio-
demographic differences) of hospitals selected
• Maximum of 4 sites chosen from any one research
network
• No more than 3 hospitals from the same country
• Emails inviting physicians to participate will be distributed
to the existing Pediatric Emergency Research Network
(PERN) asthma working group
• Aim to include both tertiary paediatric centres and mixed
hospitals
Participant selection • Each hospital to arrange interviews with the family
members of 2 patients. The patient will also be able to
participate if deemed mature enough by their parent/
carer
• Eligibility: admitted to the hospital via the emergency
department (ED) with an acute exacerbation of asthma
• Family to be approached while the child is still an
inpatient on the hospital ward, once the child is stable
• Working group members will be eligible to be
interviewed
• Group members will also be asked to approach a local
colleague from another medical discipline (e.g.
emergency physician, paediatrician, intensivist or
respiratory paediatrician) to seek their participation
• Maximum of 5 clinicians from any single country
• No more than 2 clinicians from the same hospital
Interview format • Semi-structured face-to-face interviews by local investiga-
tors at each site
• Interview will take place at the patient’s bedside, or in an
interview room within the ward setting
• Audio recorded and transcribed
• Semi-structured telephone interview by the central study
investigators (CG and JMcC), based in Adelaide, Australia
• Interviews will be conducted in English, using telephone
or Internet-based telecommunication (e.g. Skype)
• Audio recorded and transcribed
Thematic analysis
taxonomy
• Outcomes in medical research, comprising mortality/
survival, physiological/clinical, life impact, resource use,
and adverse events/effects [42]
• Outcomes in medical research, comprising mortality/
survival, physiological/clinical, life impact, resource use,
and adverse events/effects [42]
• Theoretical domains framework [43]
Review of patient cohort
and determination of
thematic saturation
• After re-coding and analysis of 2 interviews from 5 partici-
pating sites (a total of 10 interviews), the project steering
group will review the content of the themes obtained,
and assess the demographic and clinical characteristics of
participating families
• Aim to balance between patient age, severity of asthma
exacerbation, and whether or not the patient has had
previous exacerbations
• Determine whether further interviews need to be
conducted in a particular population. For example, the
steering group may recommend more recruitment of pre-
schoolers vs school-aged children, those with severe/life-
threatening asthma vs those with milder disease, those
from low-to-middle income countries vs high-income
countries, or those with previous asthma exacerbations vs
those with a first episode
• Interview schedule will be reviewed to determine if any
changes are required
• After re-coding and analysis of interviews from 5 partici-
pating sites (a total of 10 interviews), the project steering
group will review the content of the themes obtained,
and assess the demographic characteristics of participat-
ing clinicians
• Aim to balance between type of health system (high-
income country vs low-to-middle income country), and
type of practitioner (emergency specialist vs paediatrician
vs intensivist)
• Determine whether further interviews need to be
conducted in a particular population. For example, the
steering group may recommend more recruitment of
paediatricians or intensivists, or more recruitment from
high-income countries





• Reassessment every 5 interviews after the initial 10 until it is determined that thematic saturation is reached and that a
representative sample of all important patient types has been achieved
• Thematic saturation reached when 3 consecutive interviews have been completed with no new themes emerging
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researchers will be asked for details of their place of
work and role (emergency physician, paediatrician,
intensivist, etc.), whilst patients/family members will be
asked for details on their most recent hospital experi-
ence, and number of hospitalizations and ICU admis-
sions. To enable identification of individuals completing
each round, each participant will be allocated a unique
identifier.
The comprehensive list of outcomes will be presented
to participants in plain language. Questions will be
grouped into topics (e.g. vital signs, length of stay mea-
sures, etc.), and general questions will precede specific
ones. Participants will be asked to rate the importance of
each of the outcomes on a 9-point Likert scale, with 1
labeled as “not important”, and 9 labeled as “critical”.
There will be space for participants to provide optional
free-text comments for each choice. There will also be a
free-text box at the end of the survey for respondents to
suggest any additional outcomes not included in the
questionnaire.
Delphi round 2
Responses to the first Delphi round will be analyzed separ-
ately by the stakeholder group. No items will be removed.
Open-ended responses will be collated, translated into
English as necessary, and those suggested by two or more
respondents will be added to the initial list.
The second round of the Delphi survey will present all
items from round 1 as well as new open-ended re-
sponses. Items that were ranked in round 1 will be
presented alongside feedback to participants with pre-
sentation of scores from both the patient/family group
and the clinician/researcher group.
Delphi round 3
Items for round 3 will be based upon the results of the
second round, with inclusion if they are rated 7–9 (on
the 9-point Likert scale) by 50% or more participants
and 1–3 by no more than 15% of participants in at least
one stakeholder group [45]. Each item will be presented
alongside round 2 scores from both stakeholder groups.
The survey for round 3 will also allow respondents to
indicate their willingness to be contacted for a planned
face-to-face meeting within the following 6–12months
to discuss the results of the study and determine a final
list of outcome measures.
During all survey rounds, the questionnaires will be
designed so that participants are not able to skip any
questions or leave any questions blank, to ensure there
are no missing data.
Definition of consensus
The core set of outcomes from the Delphi survey will be
selected after the third round of the survey according to
the following criteria: (1) 70% of participants scoring
outcomes as 7–9 and 15% or less scoring 1–3 by both
stakeholder groups; or (2) 90% or more scoring 7–9
from either stakeholder group [45].
Project 3: reviewing current assessment tools for bedside
assessment of asthma severity
To understand current assessment practices, a review of
currently used clinical guidelines and inclusion criteria
for existing clinical trials is ongoing, along with a review
of the literature on bedside asthma severity scores. The
primary objective is to describe and compare acute
severity assessment recommendations on childhood
asthma exacerbations within and between geographic
regions. This will be critical to ensure that patients
enrolled in future studies of asthma treatments are
comparable across regions. Secondary objectives are to
compare management recommendations, and to assess
the quality of existing guidelines, in order to clarify the
extent to which current practice reflects the available
evidence, and highlight areas for further research.
Sampling of clinical practice guidelines
We will sample clinical practice guidelines by distribut-
ing emails inviting physicians and hospitals to participate
via the eight partner networks that contribute to PERN,
and to the clinicians associated with the PERN asthma
working group. The email recipients will be requested to
forward the email to other physicians and hospitals
within their local geographic region and/or research net-
work. The request for participation will also be shared
on social media. This snowball approach, building on
existing formal and informal professional and academic
relationships, will allow sampling within countries with-
out formal organised research networks.
Each participating hospital will be asked to provide
copies and/or web links to their current clinical asthma
guideline, and any regional or national clinical guideline.
Documents may be entitled clinical protocols, clinical
guidelines, care pathways, or other similar titles. How-
ever, for the purposes of this study, any document that
provides recommendations on severity assessment and
treatment for children > 1 year of age presenting to the
ED/hospital with acute onset of wheezing or asthma will
be considered eligible for inclusion.
The clinical guideline project has been deemed a qua-
lity assurance activity by the Monash Health Human
Research Ethics Committee (RES-18-0000-525Q), and
had obtained details of more than 110 local, national,
and international asthma guidelines by July 2019.
Data abstraction: guideline content
Components of each clinical guideline will be inde-
pendently abstracted by two reviewers. Abstracted
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data will be recorded on a purpose-designed
password-protected spreadsheet. Any discrepancies in
data abstraction between the two reviewers will be
discussed. If discrepancies remain, a third reviewer
will be consulted, and a decision will be made by
consensus.
Guidelines that are written in languages other than
English will be abstracted by two investigators who are
fluent in English and in the language in which they are
written.
Specific data will be abstracted on:
1. Definition of asthma (including age range)
2. Assessment of acute asthma severity, including use
of asthma severity scores. This will include
abstraction of recommendations for when to utilise
these scores (i.e. at triage, within the ED, while an
inpatient), and whether the scores include clinical
findings only, or additional investigations.
3. Recommendations and thresholds for initiating
treatments, including:
a. Inhaled bronchodilator therapy;
b. Enteral, parenteral, or inhaled corticosteroids;
c. Adjunctive inhaled therapy;
d. IV/subcutaneous/intramuscular bronchodilator
medications;
e. Oxygen therapy (including devices and flow
rates);
f. Non-invasive or invasive ventilation;
g. Admission/discharge;
h. ICU admission/interhospital transfer;
i. Treatment at discharge;
j. Follow-up management.
4. Specific guidance for asthma complications (such as
pneumothorax, atelectasis).
5. Each recommendation will be abstracted in
terms of direction (to use/not use), and, if
available, strength of recommendation and
quality of supporting evidence. Thresholds for
treatment initiation will be abstracted according
to history, examination, bedside tests of lung
function, clinical asthma scores, and laboratory
tests.
A copy of the data abstraction sheet is provided in the
Additional file 3.
Comparisons will be made within each geographic re-
gion/research network, and across all guidelines. Specific
comparisons will be made on treatment recommenda-
tions for severe asthma within each geographic region,
including inhaled magnesium, IV beta-agonists, IV ami-
nophylline, IV magnesium, and non-invasive or invasive
ventilation. Agreement between recommendations in the
guidelines will be assessed.
Data analysis: guideline quality
Each clinical practice guideline will be assessed using the
AGREE-II instrument [51]. Each guideline will be inde-
pendently assessed by at least two appraisers to increase
the reliability of the instrument [51]. All raters will
undergo specific training on the use of the AGREE-II in-
strument. Guideline quality will be assessed overall and
for each of the six domains examined by the AGREE-II
instrument. Comparisons will be made between regions/
research networks and all other guidelines, and between
guidelines published prior to 2010 and those from 2010
and onwards.
Data management and storage
Data will be collected using a dedicated study email ad-
dress, and extracted data stored in a password-protected
electronic folder at Monash Health. Data will be stored
for 7 years after the completion of the study.
Literature search and systematic review for asthma severity
scores
We will perform a systematic review to determine the
reliability and validity of clinical bedside scores used for
assessment of asthma and/or wheeze in children. Search
terms will include “[asthma OR wheeze] AND [validity
OR validation OR reliability] AND [score OR scale OR
assessment OR index]”, with appropriate modifications
for each database, and be limited to children aged 0–18
years. We will also search for each clinical severity score
identified by sampling of clinical practice guidelines. The
search will be conducted in the Pubmed, Embase,
Cochrane library, National Guideline Clearinghouse, and
CINAHL databases. Each scoring system will be assessed
with quality criteria relating to utility, reliability, and
validity [52].
Step 4: clinical outcome prevalence in acute severe
paediatric asthma
We will conduct a multi-centre, retrospective cohort
study of eligible children diagnosed with asthma or
wheeze in 19 Australasian EDs associated with the
Paediatric Research in Emergency Departments Inter-
national Collaborative (PREDICT) network.
The study population will be children aged 1–17 years
(up to but not including 18th birthday) presenting to a
participating ED with a discharge diagnosis of asthma/
wheeze, who are administered inhaled or IV medication
or receive invasive or non-invasive respiratory support.
We will exclude children with a final ED diagnosis of
bronchiolitis and no bronchodilator administered, those
with a diagnosis of foreign body inhalation, and those
receiving IV bronchodilator treatment before arrival.
Each site investigator will identify a list of medical
records of all children meeting inclusion criteria
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presenting between 1 November 2015 and 31 October
2016. These records will be identified using the local ED
information system and hospital medical records, using
the following ICD-10 codes: “Asthma” or “Childhood
asthma” (ICD-10 code: J45, J46); “Wheezing” (ICD-10
code: R06.2); and “Acute bronchiolitis” (ICD-10 code:
J21).
Each child attending the ED with asthma/wheeze is
eligible for inclusion, even if the child has previously
been included in the study. Each record will be assigned
consecutive numbers by the medical records depart-
ment, and then be screened for eligibility. Required in-
formation will be obtained from charts by trained
abstractors.
The main outcome measure is the prevalence of IV
bronchodilator therapy administration. Secondary out-
come measures include type of bronchodilator therapy
used; non-invasive respiratory support (continuous posi-
tive airway pressure (CPAP)/bi-level positive airway
pressure (BiPap), and high-flow nasal oxygen therapy);
prevalence and duration of intubation and mechanical
ventilation; rates of hospital admission, ICU admission,
and interhospital transfers; complication rates for
pneumothorax, hypokalaemia requiring replacement
therapy, hypotension requiring an IV fluid bolus of at
least 10 mL/kg, and arrhythmias requiring electrocardio-
gram (ECG) monitoring or antiarrhythmic therapy.
Data storage and analysis
De-identified data will entered into a protected elec-
tronic database at each participating hospital using
Research Electronic Data Capture (REDCap) [53], and
be housed at a central data processing site at Murdoch
Children’s Research Institute (MCRI), Parkville, Victoria.
All study investigators and the biostatistician will have
full access to the final study dataset. The complete data
set will be analysed at Monash Children’s Hospital,
Clayton, Victoria.
Data will be descriptively analysed. Binary outcomes
will be presented as proportions with 95% confidence in-
tervals. For continuous outcomes, data will be presented
as means and standard deviations (normally distributed
data) or medians and interquartile ranges (non-para-
metric data).
For categorical data, comparisons will be made with
calculation of odds ratio, and significance determined
using chi-square analysis. For non-parametric continu-
ous data, comparisons will be made using the Mann-
Whitney U test (two-group comparisons) and the
Kruskall-Wallis test (three-group comparisons). For nor-
mally distributed continuous data, two-group compari-
sons will be made using the independent samples t test,
whilst three-group comparisons will be made using
analysis of variance (ANOVA).
Exploratory modeling analysis
Multiple logistic regression will be used to assess predic-
tors of ICU admission and other binary outcomes, whilst
multiple linear regression will be used to assess conti-
nuous outcomes such as hospital length of stay.
We will use generalized linear mixed effects models to
account for multiple admissions and clustering of pa-
tients within hospitals. Hospitals will be included as ran-
dom effects in these models and the clustered nature of
the data will be modelled by fitting the appropriate co-
variance structure. Analysis will be performed using the
PROC GLIMMIX procedure available in SAS software.
Ethical aspects
The project has been approved by the Monash Health
Human Research Ethics Committee (RES-17-0000-238
L), and site-specific approval has been obtained at each
site prior to commencement of data collection.
Sample size
The rate of administration of IV therapy for children in
Australia and New Zealand is currently unknown. Based
on the approximately 3% rate of IV therapy in the UK
study [11], we anticipate the need to review approxi-
mately 1000 eligible charts at each site to obtain 30–40
cases in which IV bronchodilators are administered.
Data collection at 19 hospitals will provide data on ap-
proximately 570 children with asthma requiring IV ther-
apy. Each site will be requested to collect data on 1000
patients or 12 months of data (whichever is less).
If more than 1000 eligible medical records are identi-
fied on the initial screen of medical records, a random
number generator will be used to create a series of ran-
dom numbers corresponding to the medical records.
Screening will then occur in order of the generated ran-
dom numbers until 1000 eligible records are identified.
This project will provide information on the incidence
of severe paediatric asthma/wheeze in Australia and
New Zealand; prevalence of complications and clinical
outcomes; and patterns of IV and other escalated ther-
apy for these children. This information will inform dis-
cusions relating to the feasibility of specific clinical
outcome measures to power trials in children with se-
vere asthma exacerbations. For example, if a particular
clinical outcome (e.g. intubation, pneumothorax) was
found to be very rare, it would not be feasible to power
a randomized controlled study to detect a clinically
meaningful difference between treatment groups for that
outcome.
Step 5: consensus meeting and next steps
Once results from steps 2, 3, and 4 are available, a half
day face-to-face meeting will be arranged in Melbourne,
Australia, in which international investigators can
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participate by teleconference. Invitations will be sent to
all study steering group members, Delphi study partici-
pants who have indicated a willingness to be involved in
such a meeting, and representatives of major stake-
holders such as general practitioners, patient advocacy
groups, and specialist medical and nursing colleges.
The meeting will enable discussion of the results of
the Delphi survey to agree a final set of core outcomes,
and undertake additional voting if required. Attendees
will be sent a reminder of their personal Delphi scoring
prior to the meeting. We will seek to ratify outcomes
that have met the predetermined definition for the Del-
phi survey, and to further discuss and then make a deci-
sion upon those outcomes that had not met the
consensus threshold prior to the meeting. Additional
discussion will then occur on how best to measure the
chosen outcomes, and identification of any further
research required to better inform decisions about
measurement.
Once the meeting has been completed, we intend to
produce a consensus statement relating to core outcome
measures in acute severe asthma. This will be drafted
and a copy circulated to all those involved in the project
for comment prior to finalization and distribution.
Trial status
At the time of submission of this paper (August 2019),
the trial status is as follows:
 Systematic review of outcome measures: completed
and published in November 2018.
 Overview of Cochrane Reviews: protocol completed
and published March 2018. Literature search and
data collection complete. Manuscript preparation
ongoing.
 Patient interviews (protocol version 1.4, date: 17
September 2018). Data collection commenced
February 2019. Anticipated completion mid-2020.
 Clinician interviews (protocol version 1.3, date: 31
August 2018). Data collection commenced May
2019. Anticipated completion mid-2020.
 Review of clinical practice guidleines (protocol
version 1.3, date: 3 August 2018). Data collection
commenced September 2018, data extraction
ongoing. Anticipated completion mid-2020.
 Retrospective cohort study (current protocol version
2.8, date: 12 December 2018 - amended due to
additional participating hospitals; original approved
protocol version 2.3, date 30 May 2017). Data
collection commenced June 2017, data collection
ongoing. Anticipated completion late 2020.
 Yet to commence: Delphi study, review of asthma
severity scores, consensus meeting.
Discussion
There is currently no published, globally applicable, core
outcome set for acute severe paediatric asthma. Studies
comparing IV treatment modalities exhibit great va-
riation in the type, number, and timing of outcome
measures used.
The development of an international consensus on
core outcomes is an important first step towards the de-
velopment of consensus guidelines and standardised
protocols for RCTs in this population. This will enable
us to better interpret and compare future studies, reduce
risks of study heterogeneity and outcome reporting bias,
and improve the evidence base for the management of
this important condition.
Once developed, we aim to disseminate our core out-
come set and consensus guidelines widely through pres-
entation at relevant scientific meetings and publication
in relevant journals. We will adhere to guidelines for
authorship outlined by the International Committee of
Medical Journal Editors [54]. We will also enable study
participants to register an email address for communica-
tion of study results.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3785-6.
Additional file 1. Interview schedule.
Additional file 2. Interview schedule.
Additional file 3. Data extraction sheet.
Additional file 4. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents.
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